Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Kira Bona, MD, MPH
Dana-Farber Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Connecticut Children'S Medical Center
Hartford, Connecticut, United States
Recruiting - Children'S Healthcare of Atlanta
Atlanta, Georgia, United States
Recruiting - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Recruiting - Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Recruiting - University of Texas Southwestern Medical Center
Dallas, Texas, United States
Recruiting - Seattle Children'S Hospital
Seattle, Washington, United States
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2025
- Primary completion
- 1 Jun 2029
- Completion
- 1 Jun 2029
- Last update posted
- 10 Feb 2026
- Registered enrollment
- 84
- Registry id
- NCT06831552
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.